Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Inclusion Criteria: Participant is ≥18 years of age; Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit; Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3); Participant has either current active PsO or a dermatologist confirmed history of PsO; Participant tests negative for rheumatoid factor (RF) at the Screening Visit; Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit; Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information. Exclusion Criteria: Participant with known hypersensitivity to sonelokimab or any of its excipients; Participant with known hypersensitivity to adalimumab or any of its excipients; Participant who has previously failed on anti-interleukin (IL)-17 therapy; Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy; Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit; Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA; Participant who has a diagnosis of arthritis mutilans